Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase 3 MCRC Trial

Friday, February 26, 2010 Cancer News
Email Print This Page Comment
Font : A-A+

Company Also Anticipates Phase 3 Results for Aptocine in HCC, Progress in Other Trials, and More Immune-Response Studies

Contacts

Llew Keltner, M.D., Ph.D.

President & CEO

425-957-8940

dr_llew@lsoncology.com

Robert M. Littauer

Vice President, Chief Financial Officer & Treasurer

425-957-8946

bobl@lsoncology.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook